叫板诺和诺德(NVO.US)和礼来(LLY.US)！罗氏(RHHBY.US)在收购Carmot后继续加码减肥药市场

智通财经网01-10

智通财经APP获悉，罗氏(RHHBY.US)在上个月达成以31亿美元收购减肥药开发商Carmot Therapeutics的协议后，继续加码减肥药市场。这家瑞士制药商周二表示，正在寻找更多的生物技术合作伙伴，以帮助其挑战减肥药物领军企业诺和诺德(NVO.US)和礼来(LLY.US)。罗氏正在寻找调节新陈代谢的新方法，最终可能与Carmot交易中获得的疗法相结合。“这为我们打开了一个全新的前景，”...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2402112710?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-01-10 11:34","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2402112710","market":"sg","top_or_hot":-1,"title":"叫板诺和诺德(NVO.US)和礼来(LLY.US)！罗氏(RHHBY.US)在收购Carmot后继续加码减肥药市场","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)在上个月达成以31亿美元收购减肥药开发商Carmot Therapeutics的协议后，继续加码减肥药市场。这家瑞士制药商周二表示，正在寻找更多的生物技术合作伙伴，以帮助其挑战减肥药物领军企业诺和诺德(NVO.US)和礼来(LLY.US)。罗氏正在寻找调节新陈代谢的新方法，最终可能与Carmot交易中获得的疗法相结合。“这为我们打开了一个全新的前景，”...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1052814.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>叫板诺和诺德(NVO.US)和礼来(LLY.US)！罗氏(RHHBY.US)在收购Carmot后继续加码减肥药市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n叫板诺和诺德(NVO.US)和礼来(LLY.US)！罗氏(RHHBY.US)在收购Carmot后继续加码减肥药市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-10 11:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1052814.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)在上个月达成以31亿美元收购减肥药开发商Carmot Therapeutics的协议后，继续加码减肥药市场。这家瑞士制药商周二表示，正在寻找更多的生物技术合作伙伴，以帮助其挑战减肥药物领军企业诺和诺德(NVO.US)和礼来(LLY.US)。罗氏正在寻找调节新陈代谢的新方法，最终可能与Carmot交易中获得的疗法相结合。“这为我们打开了一个全新的前景，”...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1052814.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0122379950.USD","symbol_name":"贝莱德世界健康科学A2","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1052814.html","article_id":"2402112710","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2402112710","pubTimestamp":1704857697,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，罗氏在上个月达成以31亿美元收购减肥药开发商Carmot Therapeutics的协议后，继续加码减肥药市场。这家瑞士制药商周二表示，正在寻找更多的生物技术合作伙伴，以帮助其挑战减肥药物领军企业诺和诺德和礼来。罗氏正在寻找调节新陈代谢的新方法，最终可能与Carmot交易中获得的疗法相结合。罗氏最近进行了一系列交易以加强其产品线，Carmot是其中之一。诺和诺德的Wegovy和礼来的Zepbound都是GLP-1类减肥药物。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SG9999014906.USD":"大华全球优质成长基金Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","RHHBY":"罗氏控股","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","03165":"华夏欧优股对冲","NVO":"诺和诺德","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","LLY":"礼来","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4534":"瑞士信贷持仓","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD"},"translate_title":"Challenge Novo Nordisk (NVO.US) and Lilly (LLY.US)! Roche (RHHBY.US) continues to overweight the diet pills market after acquiring Carmot","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":1,"NVO":1,"LLY":1,"03165":0.6},"content_text":"智通财经APP获悉，罗氏(RHHBY.US)在上个月达成以31亿美元收购减肥药开发商Carmot Therapeutics的协议后，继续加码减肥药市场。这家瑞士制药商周二表示，正在寻找更多的生物技术合作伙伴，以帮助其挑战减肥药物领军企业诺和诺德(NVO.US)和礼来(LLY.US)。罗氏正在寻找调节新陈代谢的新方法，最终可能与Carmot交易中获得的疗法相结合。“这为我们打开了一个全新的前景，”罗氏合作主管James Sabry表示。罗氏最近进行了一系列交易以加强其产品线，Carmot是其中之一。Sabry表示，该公司还对肿瘤学、神经学、眼科以及心血管医学感兴趣。Sabry表示，虽然许多公司都在试图打入热门的减肥市场，但罗氏是为数不多的几家具有规模和全球影响力的公司之一，可以进行将新药推向市场所需的大规模、昂贵的试验。他表示，减肥药物的营销也比癌症等其他领域更为复杂，因为制药商需要与初级保健医生打交道，而不是少数专业治疗中心。“当我们试图达成交易时，我们发现肿瘤学领域有更多的竞争对手，”他表示。“你可能会认为，每个人都在和你竞争代谢药物，但事实并非如此。”罗氏是最早开发GLP-1类实验性药物的制药公司之一。诺和诺德的Wegovy和礼来的Zepbound都是GLP-1类减肥药物。但十多年前，由于患者因恶心等副作用退出了一项研究，罗氏停止研发GLP-1类药物。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2402112710"}